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Abstract
Missense somatic mutations affecting histone H3.1 and H3.3 proteins are now accepted as the hallmark of paediatric
diffuse intrinsic pontine gliomas (DIPG), non-brain stem paediatric high grade gliomas (pHGG) as well as a subset of
adult glioblastoma multiforme (GBM). Different mutations give rise to one of three amino acid substitutions at two
critical positions within the histone tails, K27M, G34R/V. Several studies have highlighted gene expression and
epigenetic changes associated with histone H3 mutations; however their precise roles in tumourigenesis remain
incompletely understood. Determining how such amino acid substitutions in a protein affect its properties can be
challenging because of difficulties in detecting and tracking mutant proteins within cells and tissues. Here we describe
a strategy for the generation of antibodies to discriminate G34R and G34V mutant histone H3 proteins from their
wild-type counterparts. Antibodies were validated by western blotting and immunocytochemistry, using recombinant
H3.3 proteins and paediatric GBM cell lines. The H3-G34R antibody demonstrated a high degree of selectivity towards
its target sequence. Accordingly, immunostaining on a cohort of 22 formalin-fixed paraffin embedded tumours with a
previously known H3.3 G34R mutation status, detected successfully the corresponding mutant protein in 11/11 G34R
cases. Since there was a high concordance between genotype and immunohistochemical analysis of G34R
mutant tumour samples, we analysed a series of tissue microarrays (TMAs) to assess the specificity of the
antibody in a range of paediatric brain tumours, and noted immunoreactivity in 2/634 cases. Importantly,
we describe the generation and validation of highly specific antibodies for G34 mutations. Overall our work adds to an
extremely valuable portfolio of antibodies, not only for histopathologic detection of tumour-associated mutant histone
sequences, but also facilitating the study of spatial/anatomical aspects of tumour formation and the identification of
downstream targets and pathways in malignant glioma progression.
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Introduction
Missense somatic mutations affecting histone H3.1 and
H3.3 proteins are highly prevalent in diffuse midline
gliomas and in a subset of hemispheric paediatric high-
grade gliomas (pHGG) [5, 8, 9, 15], for which prognosis
is very poor. The H3.3 mutation most commonly occurs in
the H3F3A gene and is associated with one of three amino
acid substitutions at two critical positions within the his-
tone tails, which are K27M, G34R and G34V; whereas the
H3.1 mutation mainly occurs in the HIST1H3B gene with
K27M substitution [5, 8, 9, 15]. As mutations affecting
regulatory genes are uncommon for diffuse intrinsic
pontine gliomas (DIPG) and pHGG, this finding is ex-
tremely striking.
Distinct differences in the temporal, spatial and anatom-
ical location of the histone H3 K27 and H3 G34 mutations
have been noted; in particular, G34 mutations are found
predominantly in supratentorial non midline tumours,
whilst K27 mutations occur in more than 70% of DIPG as
well as in mid brain tumours [5, 8, 9, 13, 15]. Importantly,
long-term survivors of DIPG did not harbour K27 muta-
tions in the H3.3 gene, with the K27 H3.3 mutation there-
fore defining a clinically and biologically distinct sub
group of DIPG [8, 9, 13].
The development of effective therapies based on the
underlying biology has been hampered by a lack of
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understanding of the molecular pathology of these
tumours, in considerable part due to the prior scarcity
of clinical tissue and patient-derived cell lines. The
K27 and G34 mutations have been found to be associ-
ated with specific anatomical locations of distinct gene
expression profiles and more recently with distinct
epigenetic subgroups [3, 4, 12, 13]. For example H3.3
mutated tumours can be identified by differential pro-
tein expression patterns; K27 are OLIG2 positive and
FOXG1 negative whilst G34 are OLIG2 negative and
FOXG1 positive [13]. Recent developments have revealed
that the H3 K27M mutation changes the epigenetic
landscape by inhibiting the methyltransferase activity of
EZH2 in the polycomb repressive complex 2 (PRC2),
which leads to global reduction of K27me3 levels [11].
Despite these insights, the mechanistic roles of different
histone mutations in gliomagenesis remain incompletely
understood and have not yet led to the realisation of
therapeutic targets [8].
To better understand the underlying biology of H3
mutations in brain tumours, different groups have ap-
plied a number of molecular approaches, including gen-
eration of a mutant selective antibody which recognises
H3.1 and H3.3 K27M mutated residues [11]. Since then,
various studies have utilised the H3-K27M antibody and
have shown it to be effective by immunohistochemistry,
where it demonstrated 100% sensitivity and specificity.
Furthermore it has proved to be superior to a H3K27me3
antibody (which is used to screen global reduction of
H3K27me3) in diagnosing H3 K27M mutations in brain
tumours [2, 14]. In this study, we report the generation
and application of novel antibodies against H3.3 G34R
and G34V mutations. H3-G34R and H3-G34V antibodies
were raised in rabbits and affinity purified. Both antibodies
could detect exogenous and endogenous H3.3 G34R/V
mutant proteins, by western blot and immunofluores-
cence methods. Importantly, the H3-G34R antibody ef-
fectively demonstrated high specificity and sensitivity to
detect the G34R mutation in brain tumour sections by
immunohistochemistry.
Materials and methods
Histone mutant specific antibody production
Rabbit polyclonal antibodies against human histone H3.3
mutant proteins (G34R and G34V) were produced via a
synthetic peptide approach with a commercial partner,
Cambridge Research Biochemicals (Billingham, Cleve-
land). Peptide sequences that showed good antigenic
probability were chosen for antibody production (Fig. 1).
The strategy was to incorporate the mutated residue cen-
trally within the peptide sequence, with five amino acids
at either side. Conjugation of the synthetic peptide to a
carrier prior to immunisation was achieved by the
addition of an N-terminal Cys residue. The immunisation
procedure was based on a 77-day schedule.
Affinity purification of antibodies and ELISA
Crude antisera were first subjected to an initial immuno-
depletion step with an excess of the wild-type peptide
sequence. A subsequent affinity-enrichment step was
performed with antibodies by using their corresponding
antigenic mutant peptides. For each rabbit the harvest
bleed was passed by gravity over the affinity media in the
column. The column was then washed with phosphate-
buffered saline (PBS). The purified antibodies were eluted
with two different pH buffers, firstly glycine buffer pH 2.5,
followed by equilibration with PBS and a further elution
with triethylamine (TEA) buffer pH 11. For the H3-G34R
antibody, an additional depletion step using the wild-type
peptide was also included as ELISA indicated residual
cross-reactivity against this sequence after the initial de-
pletion/purification step (data not shown). The eluates
were then transferred to dialysis cassettes and dialysed
against PBS, overnight with stirring at 4 °C. Antibody spe-
cificity was assessed by ELISA. 50 μl/ well of 10 μg/ml of
the relevant peptide in 1× PBS buffer was used to coat an
ELISA plate (Nuncproduct code 439454). The plate was
incubated at 37 °C for 1 h. All the washing steps were with
1× TBS-Tween 20 (0.1% (v/v) Tween 20). Samples of
crude unpurified antisera, unbound antisera from the
purification column and the purified eluates were serially
diluted from 1/50, 1/100, 1/200, 1/400, 1/800, 1/1600, 1/
3200, 1/6400, 1/12,800, 1/25,600 and 1/51,200 in PBS-
Tween 20 (0.1% (v/v) Tween 20), applied at 50 μl/well and
incubated for 60 min at 37 °C. The reagent blank con-
sisted of 50 μl PBS-Tween 20. Samples were removed and
the wells washed. Polyclonal goat anti-rabbit immuno-
globulin alkaline phosphatase secondary antibody (Vector
product code AP-1000) was diluted 1/500 in PBS-Tween
20, applied at 50 μl/well and incubated for 60 min at 37 °C.
50 μl of the alkaline phosphatase substrate (Sigma product
code N2770 p-Nitrophenyl Phosphate Tablets) was added
and incubated for 30 min at 37 °C. The absorbance was
determined at 405 nm on an Epoch Biotek plate reader. All
sample values were corrected by subtracting against the
reagent blank value, which was the average of 8 readings on
every plate.
Cell culture
Human paediatric glioblastoma (GBM) cell lines SF188
and KNS42 have been extensively characterised previ-
ously [1]. KNS42 harbours a histone H3.3 (H3F3A)
G34V mutation whilst SF188 is H3 wild-type [4]. These
cell lines were grown as monolayers in DMEM/F12
Ham’s medium (Life Technologies) supplemented with
10% fetal calf serum (GIBCO) and antibiotics at 37 °C
and 5% CO2. Paediatric pHGG cell lines HSJD-DIPG-
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012 and HSJD-GBM-002 were grown according to the
in house protocol from the Montero lab. Cells were cul-
tured as monolayers in flasks pre-treated with laminin
(10 μg/ml, BioLamina). Tumour Stem Medium (TSM)
base was prepared with 50% Neurobasal-A Medium,
50% D-MEM/F-12, 1% HEPES buffer solution (1 M), 1%
sodium pyruvate MEM Life 100MM(CE), 1% MEM
non-essential amino acids solution 10 mM (100×), 1%
GlutaMAX-I supplement and 1% antibiotic-antimycotic
(100×) (LifeTechnologies). 10% FBS was added fresh to
TSM base media for preparing a differentiation TSM
media. Cells were grown as monolayers in this media at
37 °C with 5% CO2.
Cloning, recombinant protein expression and western
blotting
A plasmid construct pGEX-H3.3 for the expression of
GST-tagged human histone H3.3 was generated by sub-
cloning the H3.3 cDNA from pCDNA4/TO-FLAG-H3.3
(Addgene) into pGEX-4 T1 in frame with the EcoRΙ and
BamHΙ sites. pGEX-H3.3 was mutated at positions
equivalent to G34R, G34V and K27M using mutant-
specific primers in an overextended PCR method. All
constructs were verified by DNA sequencing. GST-H3.3
protein expression in XL10 gold E. coli was induced by
addition of 0.2 mM isopropyl-β-D-thiogalactopyranoside
(IPTG) in the log phase of growth. PBS buffer supple-
mented with PMSF was used for re-suspension of the bac-
teria, which were lysed by sonication. Pull-downs were
performed by binding GST fusion proteins to glutathione-
Sepharose beads 4B (GE Healthcare). Sepharose-captured
proteins were then probed with antibodies as follows.
Protein were eluted from beads by boiling in an equal
volume of 2 × Laemmli buffer, then separated by elec-
trophoresis on 15% SDS-polyacrylamide gel, and trans-
ferred onto a nitrocellulose membrane. The primary
antibodies used for probing were wild-type histone H3
(Abcam ab1791) (1/2500), H3-K27M (Milipore ABE419)
(1/1000), and affinity-purified H3-G34V (1/500) and H3-
G34R (1/250) antibodies (glycine elutes from this study)
which were incubated either overnight at 4 °C or 1 h at
room temperature. The primary antibodies were detected
by horseradish peroxidase-conjugated anti-rabbit secondary
antibodies (Dako) and visualized with the Western Lighting
plus ECL detection system (Perkin Elmer). 5% (w/v) bovine
serum albumin (BSA) in PBS was used for blocking the
nitrocellulose membrane and 1% PBS-Tween was used for
all washing steps.
Immunofluorescence
KNS42, SF188, HSJD-DIPG-012 and HSJD-GBM-02
cells grown were grown on acid-treated glass coverslips
and were fixed in methanol at −20 °C. Cells were washed
in PBS, blocked with 1% (w/v) BSA in PBS and incubated
with antibodies for wild-type histone H3 (Abcam ab1791),
H3-K27M (Millipore ABE419) and affinity-purified H3-
G34V and H3-G34R antibodies (glycine eluates from this
study) diluting in 3% (w/v) BSA in PBS. Secondary
antibodies were either goat anti-rabbit AlexaFluor 488
or goat anti-rabbit 568 (Invitrogen, Molecular Probes).
Coverslips were mounted in Vectashield (Vector la-
boratories). Fluorescence microscopy was performed
with a Deltavision microscope. Images were processed
with Image J software.
Fig. 1 (Top) Human histone H3.3 protein sequence with underlined peptide sequence used for antibody production. The position of the H3
G34R/V mutations site is indicated. (Below) Schematic overview of the antibody generation protocol (H3-G34V antibody shown here) with
depletion of crude antisera on wild-type peptide prior to affinity-enrichment on the antigenic peptide
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Tumour samples and Immunohistochemistry
The first study cohort comprised 22 formalin fixed paraffin
embedded (FFPE) samples with a known histone genotype.
These tumors were diagnosed between 2002 and 2015 as
supratentorial high-grade glioma (HGGWHO III and IV:
14 grade IV glioblastomas, 3 grade III astrocytomas), 2 ana-
plastic gangliogliomas, 2 grade III oligo-astrocytomas, and
1 high grade glioma NOS. 11 HGG present with G34R
H3F3A mutation by direct genomic sequencing and 11 did
not (of the latter, 5 presented with K27M H3F3A mutation
and 6 were “wild type” (WT), but showed an identical mor-
phological and immunological phenotype with ATRX loss
of expression and strong P53 nuclear immunopositivity).
The second cohort comprised a panel of children’s TMAs
containing a range of histopathological subtypes (83
medulloblastomas, 64 CNS PNETs, 91 Low grade Gliomas
(LGGs) and 396 ependymomas) of childhood brain tu-
mours, were also stained for immunohistochemistry
(IHC) (Table 1).
Representative zinc formalin-fixed 4 μm sections or
TMA were deparaffinized and were subjected to a Ventana
autostainer (Discovery XT, Ventana Medical Systems,
Tucson, USA). A standard pretreatment protocol in-
cluded CC2 buffer and then affinity-purified rabbit
polyclonal H3-G34R or H3-G34V antibodies (glycine
elutes, diluted at 1:150 for G34R and 1:400 for G34V)
incubation for 30 min at room temperature. Antibody
binding was visualized with a ChromoMap detection
kit (Ventana, Tucson, USA). Diaminobenzidine tetra
hydrochloride (DAB, Ventana) was used as the chromogen.
Slide scanning was performed using NanoZoomer 2.ORS
(Hamamatsu photonics, Hamamatsu, Japan). Scoring was
performed by a neuropathologist, blinded to the tumor
genotype. In case of the TMA, the genotypes were not
known. A sample was considered as positive for G34R if
tumor cells showed a nuclear staining associated with the
negativity of the control endothelial cell nuclei.
Results
Determining how a disease-associated amino acid substi-
tution in a protein affects its properties can be challen-
ging because of difficulties in detecting and tracking
mutant proteins within cells/tissues. To directly address
this problem for glioma-mutant histone sequences, we
generated antibodies capable of selectively detecting
mutant proteins over wild-type counterparts. Briefly
polyclonal antibodies were raised in rabbits against syn-
thetic histone peptide sequences (identical in H3.3 and
H3.1) carrying G34R or G34V mutations, with an N-
terminal Cys residue included to allow conjugation of
synthetic peptide to carrier prior to immunisation (Fig. 1,
top). Crude antisera were immunodepleted by passing
through an excess of wild-type peptide immobilised on
beads, then affinity-purified using the immobilised corre-
sponding mutant peptides on beads, followed by final elu-
tion with either glycine or TEA buffer (Fig. 1, bottom).
Specificity of purified antibodies was first confirmed by
ELISA, against both the wild-type (depletion) and mutant
(antigen) peptides. As an exemplar, data for the H3-G34V
antibody is presented, demonstrating a strong preference
of the glycine-eluted fraction for the mutant peptide (titre
of 1:25,624 compared to titre of only 1:156 against the
wild-type peptide) (Fig. 2, left).
Next we tested the ability of the purified (glycine-eluted)
antibodies to detect the corresponding H3.3 mutant pro-
teins. Whilst the work was in progress, a H3-K27M spe-
cific antibody was also reported [11] and commercialised
and so was included in the analyses. Plasmids allowing
expression of glutathione-S-Transferase tagged (GST)-
H3.3 wild-type and mutant (G34R, G34V and K27M) pro-
teins in bacteria were generated, and used to produce the
histone sequences which were affinity-purified using
glutathione-Sepharose chromatography. Western blotting
against the GST-histone sequences using both our purified
antibodies along with the commercial H3-K27M and anti-
histone antibodies demonstrated selective detection of the
respective mutant proteins, with no obvious cross-
reactivity against the wild-type sequence (Fig. 2, right).
However, upon longer incubation periods or at higher
concentration the H3-G34V-selective antibody showed
low cross-reactivity against the G34R protein (but not
against K27M or wild-type, data not shown).
To further probe the specificity of the antibodies, we
tested if they could detect endogenously expressed
mutant H3.3 proteins. Four cell lines were cultured as
representative models; SF188 (negative control, wild-type
histone), KNS42 (H3.3-G34V), HSJD-DIPG-012 (H3.3-
K27M) and HSJD-GBM-002 (H3.3-G34R). Antibodies
were used to stain cultured cells grown in differentiating
TSM media on cover-slips and visualised by immuno-
fluorescence microscopy (Fig 3). Consistent with the low
cross-reactivity noted by western blotting (see above), our
H3-G34 V antibody showed weak nuclear staining of not
only the KNS42 (G34V) cells but also of SF188 (wild-
type), HSJD-DIPG-012 (K27M) and HSJD-GBM-002
(G34R) cells. Further purification of the H3-G34V anti-
body may enhance its usability for this application.
Table 1 H3-G34R antibody was tested by immunohistochemistry
against a panel of children’s tissue micro-array containing a range
of childhood brain tumours
Diagnosis No. of Cases stained G34R positive
Medulloblastoma 83 0
CNS PNET 64 1
Low Grade Glioma 91 1
Ependymoma 396 0
Total 634 2
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Fig. 2 (Left) ELISA showing reactivity of crude antisera (black), unbound fraction after affinity enrichment step (red), and purified antibodies in
glycine (blue) and TEA (green) elutions, against antigenic peptide (top, G34V) or the wild-type histone sequence (below). (Right) Western blot
showing purified recombinant GST-histone proteins as indicated are selectively detected with different antibodies. H3-G34R (1/250) and H3-G34V
(1/500) are antibodies generated in this study; H3-K27M (1/1000) and H3 wild-type (WT, 1/2000) are commercially available
Fig. 3 Patient-derived cell lines with indicated histone mutations stained with different antibodies (all 1:100) and detected by immunofluorescence
microscopy (H3-G34R and H3-G34V antibodies generated in this study; H3-K27M and H3 wild-type (WT) antibodies are commercially available). (Scale
bar 15 μm)
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However, the H3-G34R antibody demonstrated the
desired specificity, showing nuclear staining only of
the HSJD-GBM-002 (G34R) cells. Consequently, the
H3-G34R antibody was taken forward for further valid-
ation for immunohistochemistry using surgically resected
tissues.
Indeed staining tumour sections from a cohort of high-
grade gliomas demonstrated the specificity of our H3-G34R
antibody. Twenty-two tumour FFPE samples with known
H3 genotype (diagnosed as supratentorial high-grade
glioma, glioblastomas, astrocytomas, anaplastic ganglio-
gliomas, oligo-astrocytomas and high grade glioma)
were stained. Out of these samples 11 HGG had G34R
mutation, 5 had K27M mutation and 6 were H3 WT.
The H3-G34R antibody successfully detected the corre-
sponding endogenous H3 G34R mutant protein by immu-
nohistochemistry in all (11/11) G34R mutated tumors.
The antibody showed a strong nuclear staining in majority
of tumor cells (> 90% of tumor nuclei). Endothelial and
normal residual glial and neuronal cells were not immu-
nostained. One representative stained section shown in
Fig. 4 (top), and importantly, none of the H3.3 G34 WT
(n = 6) or K27M (n = 5) mutant tumors showed nuclear
staining with the H3-G34R antibody (Fig. 4, middle,
bottom).
Having established that the H3-G34R antibody detected
the correct mutation in HGG, we assessed the specificity
of the antibody in identification of G34R mutation against
a range of different histological subtypes of childhood
brain tumours, which include tumours previously diag-
nosed as CNS PNET, medulloblastoma, low grade glioma
and ependymoma. We evaluated staining of CBTRC
(Children’s Brain Tumour Research Centre) TMAs repre-
senting above histopathological subtypes of childhood
brain tumours, and found that where only 2 out of 634
cases were G34R positive. The positive cases were respect-
ively a low grade glioma and a CNS PNET (Tables 1 and
2). This demonstrates that the H3-G34R antibody does
not have high cross reactivity and is specific, which can be
used to rapidly detect H3.3 G34R mutants in an extensive
collection of tumour tissues.
Discussion
Childhood brain tumours are the major cause of cancer
related death in childhood. Highest amongst these are
histone 3 mutation-associated brain tumours, DIPG and
pHGG, which have dismal prognoses. Histone mutations
in brain tumours occur mainly at the K27 and G34 pos-
ition in the H3F3A gene (80% of DIPG and 30% of
pHGG), and less commonly at the K27 position in the
HIST1H3B gene [8, 9, 15]. The K27M mutation has been
shown to inhibit the methyltransferase activity of EZH2
in the PRC2 complex that leads to global reduction of
H3K27me3 levels [11]. In contrast, it is speculated that
the G34V/R mutations affect global H3K36 trimethyla-
tion by inhibiting trimethyltransferase SETD2 [8]. Al-
though there have been substantial advances in the
molecular understanding of histone mutant brain tu-
mours, we still lack rapid diagnostic tools and effective
therapeutic targets to benefit these paediatric patient
groups.
To expand our understanding of these tumours, we
have developed new polyclonal antibodies against H3-
G34R/V mutants. In order to obtain these mutant-specific
antibodies, we used a small peptide (11 residues) contain-
ing the appropriate H3.3 mutation as an antigen, to in-
duce immunogenicity in rabbits. These antibodies were
then affinity purified to further enhance their specificity. A
H3-K27M antibody has been already reported and been
commercialised by a different group [11]. Here, we have
reported the analyses and usability of our in house gener-
ated H3-G34R and H3-G34V antibodies.
Both H3-G34R and H3-G34V antibodies displayed
high titre in detecting the corresponding mutant anti-
gens by ELISA, consistent with the specific detection of
both exogenous and endogenous H3 G34R/V mutant
proteins, by western blot and immunofluorescence. The
H3-G34R antibody is now ready for further applications,
such as protein interaction and pathway analysis, to better
elucidate the pathology of pHGG. However, the H3-G34V
antibody exhibited cross reactivity with the G34R mutant
recombinant protein by western blot and displayed slight
background in the nucleus by immunofluorescence exper-
iments. Nonetheless, from our results the H3-G34R anti-
body is anticipated to have more selective and wide
applicability in the DIPG/pHGG research fields.
We next assessed the effectiveness of these antibodies
by immunohistochemical methods to diagnose the H3
G34R/V mutation associated brain tumours. The H3-
K27M antibody has previously been shown to be specific
and sensitive in detecting the H3 K27M mutation in
brain tumour sections [2, 6, 14]. In our study, we have
now successfully demonstrated that the H3-G34R anti-
body is also highly selective and sensitive in detecting
H3-G34R mutation in brain tumour sections and TMAs.
However, G34R antibody staining of TMAs revealed that
one LGG case out of 91 showed positive staining for
G34R. As this child is now deceased, we could not verify
whether it was a possible misdiagnosis or not. Unfortu-
nately further tissue was not available for histological re-
view or sequencing. The other G34R positive sample
was previously classified as a CNS PNET based on histo-
logical and previously accepted immunohistochemical
markers. This represents one out of 64 cases, and may
reflect the known challenges of diagnosis high grade
supratentorial CNS malignancies in childhood which
can now be facilitated by specific antibodies such as re-
ported here in the light of recent proposal for
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reclassification of CNS PNETs [10]. Interestingly, Gessi
et al. have recently reported G34R mutations in 4/33
CNS-PNET cases by sequencing and suggested that
these could be defined tumour subtype [7], supporting
the potential of our G34R antibody to detect G34R mu-
tation in various TMA cohorts. However, once again fur-
ther tissue was also not available for our CNS-PNET
case to histological review or sequence. It is unfortunate
that we were unable to genotype the two tumours, in
both cases the biopsy samples were very small and the
tissues predominantly used for the diagnostic process.
This limitation in part provided our motivation for gen-
erating new diagnostic tools. In the future access to a
larger cohort of H3.3 mutant tumours will allow us to
confirm the full specificity of our antibody. Considering
all of the above, our novel G34R antibody demonstrates
its utility as an effective diagnostic tool for rapid detec-
tion of the histone 3 mutational statuses of brain tu-
mours. Additionally, the H3-G34R antibody was
validated and confirmed to be suitable for chromatin im-
munoprecipitation (ChIP) analyses, by Active Motif
(Carlsbad, CA, USA) (data not shown). The ChIP grade
quality of our G34R antibody is valuable for future
Table 2 Clinical information on positive G34R tissue micro-array
cases of childhood brain tumours
Case Age at diagnosis (yrs) Sex Location
LGG 1 12.5 F Posterior Fossa
CNSs PNET 15.3 F Temporal/hippocampus
Fig. 4 H3-G34R antibody immunostaining correlates with histone H3.3 genotyping. Representative IHC using H3-G34R antibody on a H3 G34R
mutated tumor section shows a strong nuclear positivity in nearly all tumor cells but no staining in the nuclei of endothelial cells (top). WT H3
tumor is negative with H3-G34R antibody by IHC (middle). H3 K27M thalamic tumor stained negative for H3-G34R antibody by IHC (bottom). (scale
bar 100 μm)
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investigations to probe the mechanism of these H3 mu-
tant brain tumours.
Conclusions
To date no biomarker or diagnostic tool to detect H3
G34R/V mutant tumours is available for the clinical or la-
boratory setting. The H3-G34R/V antibodies described
here have the potential to be effective in this regard. Our
G34R antibody is highly selective, and now ready for use
in further research in patient diagnostic purposes. Further-
more, these antibodies will provide a valuable tool to pro-
mote our understanding of the molecular biology of H3
G34R/V mutant brain tumours in comparison with the
H3 K27M mutant tumours. However, only a large-scale
evaluation of these antibodies can reveal their true benefit.
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